Lung V1 predicts immunotherapy initiation after chemoradiotherapy in stage III NSCLC
In 452 stage III NSCLC patients, lower lung V1 was associated with subsequent immunotherapy initiation; an internally validated model achieved AUC 0.71.
In 452 stage III NSCLC patients, lower lung V1 was associated with subsequent immunotherapy initiation; an internally validated model achieved AUC 0.71.
Among 307 patients with extensive-stage SCLC, overall survival did not significantly differ between consolidative and progression-triggered thoracic RT, including after matching.
In de novo metastatic HNSCC, locoregional radiotherapy and first-line immunotherapy were independently associated with longer overall survival.
Organ preservation after immunotherapy-based TNT was associated with better quality of life and markedly lower risk of major bowel dysfunction than TME.
No positive lymph nodes were found in ypT0–1 tumours after immunotherapy-based TNT, supporting further study of local excision.
A single-arm phase 1/2 trial reported a 39.1% pathologic complete response rate among resected patients, with grade 4 toxicities in 10%.